Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

Demand Grows for Cancer R&D Executives

Authored by Karl Simpson Published: 22/07/2014 The recent acquisition of Norway’s biotech frontrunner, Algeta, by Bayer for $2.9 billion, purchasing their exciting new prostate cancer drug Xofigo, has brought considerable attention on Oslo, a small biotech market by global standards, … Continue reading

Posted in Recruitment Market | Tagged , , , , , , | Leave a comment

Unum Therapeutics appoints SVP Operations

Unum Therapeutics, a biotech out of Cambridge, Massachusetts  which is developing a universal cellular immunotherapy to treat multiple cancers, has hired Geoffrey Hodge as Senior Vice President, Operations, effective immediately. Mr. Hodge will be responsible for leading both technical operations, … Continue reading

Posted in Executive Appointments | Tagged , , , , , , , , , , , , | Leave a comment

Genentech pays $150m for NewLink’s oncology drug

Authored by James Sheppard Global biotech giant Genentech, part of Roche, announced a partnership with Iowa based biotech company NewLink Genetics. The partnership could be worth in excess of $1bn for NewLink if there assets hit certain predefined milestones. Genentech … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , | Leave a comment

Vaccibody successfully completes 35m NOK financing round

Authored by James Sheppard The Oslo biotech cluster based Vaccibody announced that it had successfully completed a 35m NOK (US $6m) financing round. The money has been raised via the public market in Norway by issuing new shares with new … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

ADC Therapeutics executives on fast track with funding and partners

Authored by James Sheppard ADC Therapeutics was launched in 2012 after Auven Therapeutics (previously known as Celtic Therapeutics) launched the company with initial funding of $50m. These funds were further added to buy Auven Therapeutics and Medimmune (part of AstraZeneca) … Continue reading

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Swedish Pharmalink receives Orphan Drug Approval for Busulipo

Authored by James Sheppard The Swedish speciality pharmaceutical company Pharmalink AB announced that it had received Orphan Drug approval from the US FDA for oncology conditioning agent Busulipo. Busulipo is indicated for use in cancer patients prior to hematopoietic stem … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

AstraZeneca makes play in ADC market

Authored by James Sheppard Global pharmaceutical giant AstraZeneca has recently announced the acquisition of UK based antibody-drug conjugate (ADC) specialist Spirogen. The deal will put Spirogen as part of AstraZeneca’s biologics unit, MedImmune. The deal is worth an estimated $440m … Continue reading

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Pfizer gains experimental drug from Gliknik

Authored by James Sheppard Global pharmaceutical giant Pfizer has signed a deal with tiny US biotech Gliknik for the experimental drug GL-2045. GL-2045 is being developed for the treatment of autoimmune diseases and cancer. As part of the deal, Gliknik … Continue reading

Posted in Pharmaceutical business | Tagged , , , , , , , , , , , , , , , | Leave a comment

AnaptysBio expands its cancer immunotherapy portfolio

Authored by Karl Simpson Anti-PD1 Antibody combined with TIM-3 and LAG-3 antagonists  Cancer Immunotherapy is an area that is gaining increasing levels of interest across the cancer therapeutics markets and in the life sciences market in general. This year, new … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Novartis scores FDA breakthrough-designation for rare disease product

Authored by Karl Simpson Breakthrough Therapy designation has been given by the FDA to Novartis for their development asset , which is an orphan drug being developed to treat patients with sporadic inclusion body myositis, a rare and potentially life … Continue reading

Posted in Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap